Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
128 Leser
Artikel bewerten:
(0)

CluePoints Appoints Richard Young as Chief Strategy Officer

KING OF PRUSSIA, Pa., Oct. 28, 2024 /PRNewswire/ -- RBQM innovator CluePoints has today announced that Richard Young has been appointed as its new Chief Strategy Officer. With 30 years of experience in clinical data management, Richard is an expert in his field.

Richard has previous experience at Medidata, Cmed Group and PAREXEL International. His most recent role was Vice President, Strategy, Clinical Data, at Veeva Systems. Richard has also acted as the Conference Committee Leader for the SCDM Annual Conference for the past three years, and is currently leading their innovations committee. His wealth of experience will ensure CluePoints' continued growth and development as the leading provider of integrated data review software.

Andy Cooper, CEO at CluePoints, commented: "At CluePoints we are committed to innovation and turning data into positive outcomes in clinical trials. Richard has extensive experience of clinical data management and data review, and is a well-regarded expert in his field. His thought leadership is exemplified through his successful podcast series and work on industry forums. Richard sees the journey we are on, our mission to provide the best-in-class integrated data interrogation and risk management platform, and wants to support us on that continued journey."

Richard Young reinforced the opportunities on offer: "Our industry is living through a digital inflection point, with technology offering us the opportunity to fuel and deliver step changes into global healthcare. Having successfully delivered Veeva Clinical Data, I want to contribute to the next step in realizing the potential for data to reshape and redefine research and development. I believe CluePoints is the perfect place to do that."

Andy Cooper, CEO at CluePoints, added: "Richard will drive the strategy for our product portfolio ensuring the value of our products is aligned with our customers' needs and we are planning, not just for what is needed this year, but what is needed in five years' time. He will ensure we remain a leader in RBQM while also establishing ourselves as the market leader for integrated AI-driven SaaS solutions to analyze and interrogate clinical trial data."

To learn more about CluePoints' award-winning solutions, please visit www.cluepoints.com

About CluePoints

CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.

Cision View original content:https://www.prnewswire.co.uk/news-releases/cluepoints-appoints-richard-young-as-chief-strategy-officer-302288017.html

© 2024 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.